Micafungin Pharmazac

Micafungin, the active ingredient in Micafungin Pharmazac, is an echinocandin presented as an injectable solution for intravenous use. It treats invasive candidiasis and related fungal infections in immunocompromised patients.

GNH USA supplies Micafungin Pharmazac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal that targets invasive Candida infections.

- Invasive candidiasis: treatment of bloodstream and deep‑seated Candida infections in adult and pediatric patients. - Esophageal candidiasis: eradication of Candida infection of the esophagus, improving swallowing and reducing pain. - Prophylaxis in hematopoietic stem cell transplantation: prevention of Candida infections in patients undergoing transplant procedures. - Candida peritonitis and intra‑abdominal infections: adjunctive therapy to control intra‑abdominal fungal contamination.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature during infusion. - Nausea: mild gastrointestinal upset. - Headache: occasional mild to moderate headache. - Infusion‑related reactions: flushing, chills, or erythema at the site. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Severe hepatic failure: marked elevation of liver enzymes with jaundice. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Severe hypersensitivity: including angioedema or Stevens‑Johnson syndrome. - Renal failure: acute kidney injury in susceptible patients. - Cardiac arrhythmia: rare reports of QT prolongation. - Disseminated infection: paradoxical worsening of fungal disease.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor organ function.

- Renal function: monitor serum creatinine and adjust therapy if impairment occurs. - Hepatic function: check baseline liver enzymes and repeat during treatment. - Concomitant azole antifungals: avoid co‑administration due to potential pharmacokinetic interactions. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Drug hypersensitivity: discontinue immediately if severe allergic reactions develop. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Cytochrome P450 inducers (e.g., rifampin): may markedly reduce micafungin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase micafungin plasma concentrations. - Co‑administration with other echinocandins: additive toxicity risk.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may raise micafungin levels, requiring dose observation. - Immunosuppressants (e.g., tacrolimus, cyclosporine): monitor drug levels for possible elevation. - Warfarin: monitor INR closely as micafungin may affect anticoagulation.